Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

• Franck E. Nicolini,
• H. Jean Khoury,
• Luke Akard,
• Delphine Rea,
• Hagop Kantarjian,
• Michele Baccarani,
• Janis Leonoudakis,
• Adam Craig,
• Annie-Claude Benichou,
• Jorge Cortes

Affiliations

Franck E. Nicolini

Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France

H. Jean Khoury

Emory University School of Medicine, Atlanta, Georgia, USA

Luke Akard

Indiana Blood and Marrow Transplantation at St. Francis Health, Indianapolis, Indiana, USA

Delphine Rea

Service des Maladies du Sang, EA3518 and CIC, Hôpital Saint-Louis, Paris, France

Hagop Kantarjian

University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Michele Baccarani

University of Bologna, Bologna, Italy

Janis Leonoudakis

Powered 4 Significance LLC, Bloomsbury, New Jersey, USA

Adam Craig

formerly of ChemGenex Pharmaceuticals, an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel

Annie-Claude Benichou

formerly of ChemGenex Pharmaceuticals, an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel

Jorge Cortes

University of Texas MD Anderson Cancer Center, Houston, Texas, USA